Nuvation Bio (NUVB) Gains from Investment Securities (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Gains from Investment Securities of -$2.9 million for Q1 2026, down 481.49% year-over-year from $751000.0 in Q1 2025, and down 354.21% quarter-over-quarter from $1.1 million in Q4 2025.
Nuvation Bio (NUVB) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Gains from Investment Securities for 7 consecutive years, with -$2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 481.49% year-over-year to -$2.9 million; the TTM figure through Mar 2026 stood at -$2.8 million (down 1329.82% YoY), while the FY2025 annual figure was $812000.0, down 13.25% from the prior year.
- Gains from Investment Securities slipped to -$2.9 million in Q1 2026 per NUVB's latest filing, from $1.1 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.5 million in Q1 2024 and bottomed at -$6.3 million in Q1 2022.
- Historically, Gains from Investment Securities has averaged -$694176.5 across 5 years, with a median of -$383000.0 in 2023.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities slumped 2258.36% — and 2024, when it surged 1127.46%.
- Nuvation Bio's Gains from Investment Securities stood at -$321000.0 in 2022, then advanced by 26.17% to -$237000.0 in 2023, then soared by 583.12% to $1.1 million in 2024, then dropped by 1.57% to $1.1 million in 2025, then sank by 354.21% to -$2.9 million in 2026.
- Business Quant data shows NUVB's Gains from Investment Securities at -$2.9 million in Q1 2026, $1.1 million in Q4 2025, and -$612000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.87 Mn |
| Mar 31, 2026 | -2.87 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | -612,000.00 |
| Sep 30, 2025 | -612,000.00 |
| Jun 30, 2025 | -454,000.00 |
| Jun 30, 2025 | -454,000.00 |
| Mar 31, 2025 | 751,000.00 |
| Mar 31, 2025 | 751,000.00 |
| Dec 31, 2024 | 1.15 Mn |
| Dec 31, 2024 | 1.15 Mn |
| Sep 30, 2024 | -533,000.00 |
| Sep 30, 2024 | -533,000.00 |
| Jun 30, 2024 | -1.14 Mn |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | -237,000.00 |
| Dec 31, 2023 | -237,000.00 |